Argos Therapeutics Inc (ARGS) Insider Sells $16,040.00 in Stock

Argos Therapeutics Inc (NASDAQ:ARGS) insider Charles A. Nicolette sold 100,250 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.16, for a total transaction of $16,040.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Argos Therapeutics Inc (ARGS) traded down $0.53 during trading on Friday, reaching $2.17. 877,598 shares of the company were exchanged, compared to its average volume of 218,532. The company has a debt-to-equity ratio of -1.46, a quick ratio of 2.29 and a current ratio of 2.29. Argos Therapeutics Inc has a 12 month low of $2.00 and a 12 month high of $106.00.

Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.00) earnings per share for the quarter.

An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. acquired a new position in Argos Therapeutics Inc (NASDAQ:ARGS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned 1.21% of Argos Therapeutics at the end of the most recent reporting period. 18.35% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Argos Therapeutics Inc (ARGS) Insider Sells $16,040.00 in Stock” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply